{"id":627,"date":"2009-11-30T21:53:58","date_gmt":"2009-12-01T02:53:58","guid":{"rendered":"http:\/\/blogs.nejm.org\/?p=627"},"modified":"2009-11-30T21:53:58","modified_gmt":"2009-12-01T02:53:58","slug":"who-hiv-treatment-guidelines-updated","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/who-hiv-treatment-guidelines-updated\/2009\/11\/30\/","title":{"rendered":"WHO HIV Treatment Guidelines Updated"},"content":{"rendered":"<p>This <a href=\"http:\/\/www.who.int\/mediacentre\/news\/releases\/2009\/world_aids_20091130\/en\/index.html\" target=\"_blank\">just in<\/a>:<\/p>\n<blockquote><p><span>WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells\/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms.<\/span><\/p><\/blockquote>\n<p>Which makes eminent sense, of course.\u00a0  Because if starting HIV therapy might prolong survival in developed countries, why shouldn&#8217;t it do the same in the developing world?<\/p>\n<p>In fact, when you consider the higher incidence of TB and invasive bacterial infections in such settings, it could easily be argued &#8212; and <em>has <\/em>been argued &#8212; that starting early would net greater survival gains in resource-poor settings than it would here.<\/p>\n<p>Plus, there&#8217;s the <a href=\"http:\/\/blogs.nejm.org\/index.php\/2009\/07\/25\/ias-cape-town-2009-some-greatest-hits\/\" target=\"_blank\">CIPRAHT001 Study<\/a>, which proves it.<\/p>\n<p>But there&#8217;s more &#8212; the new WHO guidelines also urge that countries\u00a0 &#8220;phase out&#8221; the use of stavudine in favor of less-toxic NRTIs, and that women continue breastfeeding so long as they are also on ART.<\/p>\n<p>Good news all around.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This just in: WHO is now recommending that ART be initiated at a higher CD4 threshold of 350 cells\/mm3 for all HIV-positive patients, including pregnant women, regardless of symptoms. Which makes eminent sense, of course.\u00a0 Because if starting HIV therapy might prolong survival in developed countries, why shouldn&#8217;t it do the same in the developing [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,4,8,9],"tags":[44,77,78,83,397,423,452,498,994],"class_list":["post-627","post","type-post","status-publish","format-standard","hentry","category-health-care","category-hiv","category-patient-care","category-policy","tag-aids","tag-antiretroviral-therapy","tag-antiretrovirals","tag-art","tag-guidelines","tag-hiv","tag-hiv-treatment","tag-infectious-diseases","tag-who"],"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/comments?post=627"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/posts\/627\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/media?parent=627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/categories?post=627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/hiv-id-observations\/index.php\/wp-json\/wp\/v2\/tags?post=627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}